Stock Track | MEDBOT-B Soars 5.03% on Regulatory Approval for New Surgical Robot Product

Stock Track

Feb 12

Shares of Shanghai Microport MedBot Group Co Ltd (02252), or MEDBOT-B, surged 5.03% in intraday trading on Wednesday following news that the company received regulatory approval for its new surgical robot system in China.

The rally came after MEDBOT-B announced that it had obtained approval from China's National Medical Products Administration (NMPA) for its Toumai Single-Arm & Single-Port Laparoscopic Surgical Robot. This innovative robotic system is designed to assist surgeons in performing minimally invasive laparoscopic procedures through a single small incision.

The regulatory green light marks a significant milestone for MEDBOT-B and paves the way for the commercialization of its cutting-edge surgical robot technology in the rapidly growing Chinese healthcare market. Investors welcomed the positive development, driving the company's stock higher on optimism over its growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1136091309"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136091309\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136091309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136091309","market":"hk","top_or_hot":-1,"title":"Stock Track | MEDBOT-B Soars 5.03% on Regulatory Approval for New Surgical Robot Product","media":"Stock Track","content":"<p>Shares of Shanghai Microport MedBot Group Co Ltd (02252), or MEDBOT-B, surged 5.03% in intraday trading on Wednesday following news that the company received regulatory approval for its new surgical robot system in China.</p>\n\n<p>The rally came after MEDBOT-B announced that it had obtained approval from China's National Medical Products Administration (NMPA) for its Toumai Single-Arm & Single-Port Laparoscopic Surgical Robot. This innovative robotic system is designed to assist surgeons in performing minimally invasive laparoscopic procedures through a single small incision.</p>\n\n<p>The regulatory green light marks a significant milestone for MEDBOT-B and paves the way for the commercialization of its cutting-edge surgical robot technology in the rapidly growing Chinese healthcare market. Investors welcomed the positive development, driving the company's stock higher on optimism over its growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MEDBOT-B Soars 5.03% on Regulatory Approval for New Surgical Robot Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MEDBOT-B Soars 5.03% on Regulatory Approval for New Surgical Robot Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-12 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Shanghai Microport MedBot Group Co Ltd (02252), or MEDBOT-B, surged 5.03% in intraday trading on Wednesday following news that the company received regulatory approval for its new surgical robot system in China.</p>\n\n<p>The rally came after MEDBOT-B announced that it had obtained approval from China's National Medical Products Administration (NMPA) for its Toumai Single-Arm & Single-Port Laparoscopic Surgical Robot. This innovative robotic system is designed to assist surgeons in performing minimally invasive laparoscopic procedures through a single small incision.</p>\n\n<p>The regulatory green light marks a significant milestone for MEDBOT-B and paves the way for the commercialization of its cutting-edge surgical robot technology in the rapidly growing Chinese healthcare market. Investors welcomed the positive development, driving the company's stock higher on optimism over its growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1136091309","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136091309","pubTimestamp":1739323979,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Shanghai Microport MedBot Group Co Ltd , or MEDBOT-B, surged 5.03% in intraday trading on Wednesday following news that the company received regulatory approval for its new surgical robot system in China.The rally came after MEDBOT-B announced that it had obtained approval from China's National Medical Products Administration  for its Toumai Single-Arm & Single-Port Laparoscopic Surgical Robot. This innovative robotic system is designed to assist surgeons in performing minimally invasi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"新手术机器人产品获监管部门批准，股票赛道MEDBOT-B飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"Shares of Shanghai Microport MedBot Group Co Ltd (02252), or MEDBOT-B, surged 5.03% in intraday trading on Wednesday following news that the company received regulatory approval for its new surgical robot system in China.\nThe rally came after MEDBOT-B announced that it had obtained approval from China's National Medical Products Administration (NMPA) for its Toumai Single-Arm & Single-Port Laparoscopic Surgical Robot. This innovative robotic system is designed to assist surgeons in performing minimally invasive laparoscopic procedures through a single small incision.\nThe regulatory green light marks a significant milestone for MEDBOT-B and paves the way for the commercialization of its cutting-edge surgical robot technology in the rapidly growing Chinese healthcare market. Investors welcomed the positive development, driving the company's stock higher on optimism over its growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}